APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Mild Moderate Primary Hypertension Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Mild Moderate Primary Hypertension Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174013460330 December 2025186 pages

Choose your research edition.

Industry ResearchMild Moderate Primary Hypertension Drugs Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Mild Moderate Primary Hypertension Drugs Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Mild Moderate Primary Hypertension Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mild Moderate Primary Hypertension Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Mild Moderate Primary Hypertension Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Mild Moderate Primary Hypertension Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Mild Moderate Primary Hypertension Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Mild Moderate Primary Hypertension Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mild Moderate Primary Hypertension Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Mild Moderate Primary Hypertension Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Mild Moderate Primary Hypertension Drugs include Zhejiang Multinpharma Co., Ltd., SHANDONG QIDU PHARMACEUTICAL CO.,LTD., Novartis, NanJing EASEHEAL Pharmaceutieal Co.,Ltd., Lianhuan Pharma, China Resources Double-Crane Pharmaceutical Co.,Ltd., LIFEON GROUP, Beijing UNION Pharmaceutical FACTORY and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Mild Moderate Primary Hypertension Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Mild Moderate Primary Hypertension Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Mild Moderate Primary Hypertension Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Mild Moderate Primary Hypertension Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Mild Moderate Primary Hypertension Drugs Segment by Company

Zhejiang Multinpharma Co., Ltd.

SHANDONG QIDU PHARMACEUTICAL CO.,LTD.

Novartis

NanJing EASEHEAL Pharmaceutieal Co.,Ltd.

Lianhuan Pharma

China Resources Double-Crane Pharmaceutical Co.,Ltd.

LIFEON GROUP

Beijing UNION Pharmaceutical FACTORY

AstraZeneca

Mild Moderate Primary Hypertension Drugs Segment by Type

Mild Essential Hypertension Drugs

Moderate Essential Hypertension Drugs

Mild Moderate Primary Hypertension Drugs Segment by Application

Medical

Others

Mild Moderate Primary Hypertension Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mild Moderate Primary Hypertension Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mild Moderate Primary Hypertension Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mild Moderate Primary Hypertension Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Mild Moderate Primary Hypertension Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Mild Moderate Primary Hypertension Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Mild Moderate Primary Hypertension Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Mild Moderate Primary Hypertension Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Mild Moderate Primary Hypertension Drugs Industry Trends Table 2. Mild Moderate Primary Hypertension Drugs Industry Drivers Table 3. Mild Moderate Primary Hypertension Drugs Industry Opportunities and Challenges Table 4. Mild Moderate Primary Hypertension Drugs Industry Restraints Table 5. Global Mild Moderate Primary Hypertension Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Mild Moderate Primary Hypertension Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Manufacturers Table 9. Global Mild Moderate Primary Hypertension Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Mild Moderate Primary Hypertension Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Mild Moderate Primary Hypertension Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Mild Moderate Primary Hypertension Drugs Manufacturers, Product Type & Application Table 13. Global Mild Moderate Primary Hypertension Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Mild Moderate Primary Hypertension Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Mild Essential Hypertension Drugs Table 17. Major Manufacturers of Moderate Essential Hypertension Drugs Table 18. Global Mild Moderate Primary Hypertension Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Mild Moderate Primary Hypertension Drugs Sales by Type (2021-2026) & (K Units) Table 20. Global Mild Moderate Primary Hypertension Drugs Sales by Type (2027-2032) & (K Units) Table 21. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Type (2021-2026) Table 22. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Type (2027-2032) Table 23. Global Mild Moderate Primary Hypertension Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Mild Moderate Primary Hypertension Drugs Revenue by Type (2021-2026) & (K Units) Table 25. Global Mild Moderate Primary Hypertension Drugs Revenue by Type (2027-2032) & (K Units) Table 26. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Type (2021-2026) Table 27. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Medical Table 29. Major Manufacturers of Others Table 30. Global Mild Moderate Primary Hypertension Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global Mild Moderate Primary Hypertension Drugs Sales by Application (2021-2026) & (K Units) Table 32. Global Mild Moderate Primary Hypertension Drugs Sales by Application (2027-2032) & (K Units) Table 33. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Application (2021-2026) Table 34. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Application (2027-2032) Table 35. Global Mild Moderate Primary Hypertension Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Mild Moderate Primary Hypertension Drugs Revenue by Application (2021-2026) & (K Units) Table 37. Global Mild Moderate Primary Hypertension Drugs Revenue by Application (2027-2032) & (K Units) Table 38. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Application (2021-2026) Table 39. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Application (2027-2032) Table 40. Global Mild Moderate Primary Hypertension Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global Mild Moderate Primary Hypertension Drugs Sales by Region (2021-2026) & (K Units) Table 42. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Region (2021-2026) Table 43. Global Mild Moderate Primary Hypertension Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global Mild Moderate Primary Hypertension Drugs Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Mild Moderate Primary Hypertension Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2026) & (K Units) Table 47. North America Mild Moderate Primary Hypertension Drugs Sales by Country (2027-2032) & (K Units) Table 48. Europe Mild Moderate Primary Hypertension Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2026) & (K Units) Table 50. Europe Mild Moderate Primary Hypertension Drugs Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific Mild Moderate Primary Hypertension Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific Mild Moderate Primary Hypertension Drugs Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa Mild Moderate Primary Hypertension Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa Mild Moderate Primary Hypertension Drugs Sales by Country (2027-2032) & (K Units) Table 57. Global Mild Moderate Primary Hypertension Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Mild Moderate Primary Hypertension Drugs Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Mild Moderate Primary Hypertension Drugs Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Region (2021-2026) Table 61. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Region (2027-2032) Table 62. Zhejiang Multinpharma Co., Ltd. Company Information Table 63. Zhejiang Multinpharma Co., Ltd. Business Overview Table 64. Zhejiang Multinpharma Co., Ltd. Mild Moderate Primary Hypertension Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Zhejiang Multinpharma Co., Ltd. Mild Moderate Primary Hypertension Drugs Product Portfolio Table 66. Zhejiang Multinpharma Co., Ltd. Recent Development Table 67. SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Company Information Table 68. SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Business Overview Table 69. SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Mild Moderate Primary Hypertension Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Mild Moderate Primary Hypertension Drugs Product Portfolio Table 71. SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Recent Development Table 72. Novartis Company Information Table 73. Novartis Business Overview Table 74. Novartis Mild Moderate Primary Hypertension Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Novartis Mild Moderate Primary Hypertension Drugs Product Portfolio Table 76. Novartis Recent Development Table 77. NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Company Information Table 78. NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Business Overview Table 79. NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Mild Moderate Primary Hypertension Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Mild Moderate Primary Hypertension Drugs Product Portfolio Table 81. NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Recent Development Table 82. Lianhuan Pharma Company Information Table 83. Lianhuan Pharma Business Overview Table 84. Lianhuan Pharma Mild Moderate Primary Hypertension Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Lianhuan Pharma Mild Moderate Primary Hypertension Drugs Product Portfolio Table 86. Lianhuan Pharma Recent Development Table 87. China Resources Double-Crane Pharmaceutical Co.,Ltd. Company Information Table 88. China Resources Double-Crane Pharmaceutical Co.,Ltd. Business Overview Table 89. China Resources Double-Crane Pharmaceutical Co.,Ltd. Mild Moderate Primary Hypertension Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. China Resources Double-Crane Pharmaceutical Co.,Ltd. Mild Moderate Primary Hypertension Drugs Product Portfolio Table 91. China Resources Double-Crane Pharmaceutical Co.,Ltd. Recent Development Table 92. LIFEON GROUP Company Information Table 93. LIFEON GROUP Business Overview Table 94. LIFEON GROUP Mild Moderate Primary Hypertension Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. LIFEON GROUP Mild Moderate Primary Hypertension Drugs Product Portfolio Table 96. LIFEON GROUP Recent Development Table 97. Beijing UNION Pharmaceutical FACTORY Company Information Table 98. Beijing UNION Pharmaceutical FACTORY Business Overview Table 99. Beijing UNION Pharmaceutical FACTORY Mild Moderate Primary Hypertension Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Beijing UNION Pharmaceutical FACTORY Mild Moderate Primary Hypertension Drugs Product Portfolio Table 101. Beijing UNION Pharmaceutical FACTORY Recent Development Table 102. AstraZeneca Company Information Table 103. AstraZeneca Business Overview Table 104. AstraZeneca Mild Moderate Primary Hypertension Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. AstraZeneca Mild Moderate Primary Hypertension Drugs Product Portfolio Table 106. AstraZeneca Recent Development Table 107. Key Raw Materials Table 108. Raw Materials Key Suppliers Table 109. Mild Moderate Primary Hypertension Drugs Distributors List Table 110. Mild Moderate Primary Hypertension Drugs Customers List Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Mild Moderate Primary Hypertension Drugs Product Image Figure 2. Global Mild Moderate Primary Hypertension Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mild Moderate Primary Hypertension Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Mild Moderate Primary Hypertension Drugs Sales (2021-2032) & (K Units) Figure 5. Global Mild Moderate Primary Hypertension Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Mild Moderate Primary Hypertension Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Mild Essential Hypertension Drugs Image Figure 9. Moderate Essential Hypertension Drugs Image Figure 10. Global Mild Moderate Primary Hypertension Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Mild Moderate Primary Hypertension Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Type (2021-2032) Figure 13. Global Mild Moderate Primary Hypertension Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Type (2021-2032) Figure 16. Medical Image Figure 17. Others Image Figure 18. Global Mild Moderate Primary Hypertension Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Mild Moderate Primary Hypertension Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Application (2021-2032) Figure 21. Global Mild Moderate Primary Hypertension Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Application (2021-2032) Figure 24. North America Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America Mild Moderate Primary Hypertension Drugs Sales Market Share by Country (2021-2032) Figure 26. U.S. Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Mild Moderate Primary Hypertension Drugs Sales Market Share by Country (2021-2032) Figure 31. Germany Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Mild Moderate Primary Hypertension Drugs Sales Market Share by Country (2021-2032) Figure 38. China Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Mild Moderate Primary Hypertension Drugs Sales Market Share by Country (2021-2032) Figure 46. Brazil Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile Mild Moderate Primary Hypertension Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global Mild Moderate Primary Hypertension Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Mild Moderate Primary Hypertension Drugs Revenue (2021-2032) & (US$ Million) Figure 57. North America Mild Moderate Primary Hypertension Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Mild Moderate Primary Hypertension Drugs Revenue (2021-2032) & (US$ Million) Figure 59. Europe Mild Moderate Primary Hypertension Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Mild Moderate Primary Hypertension Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Mild Moderate Primary Hypertension Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Mild Moderate Primary Hypertension Drugs Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Mild Moderate Primary Hypertension Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Mild Moderate Primary Hypertension Drugs Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Mild Moderate Primary Hypertension Drugs Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Mild Essential Hypertension Drugs
  • Moderate Essential Hypertension Drugs
Applications
  • Medical
  • Others
Companies covered
  • Zhejiang Multinpharma Co., Ltd.
  • SHANDONG QIDU PHARMACEUTICAL CO.,LTD.
  • Novartis
  • NanJing EASEHEAL Pharmaceutieal Co.,Ltd.
  • Lianhuan Pharma
  • China Resources Double-Crane Pharmaceutical Co.,Ltd.
  • LIFEON GROUP
  • Beijing UNION Pharmaceutical FACTORY
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Mild Moderate Primary Hypertension Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Mild Moderate Primary Hypertension Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Mild Moderate Primary Hypertension Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Mild Moderate Primary Hypertension Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Mild Moderate Primary Hypertension Drugs Market Dynamics
  1. 2.1 Mild Moderate Primary Hypertension Drugs Industry Trends
  2. 2.2 Mild Moderate Primary Hypertension Drugs Industry Drivers
  3. 2.3 Mild Moderate Primary Hypertension Drugs Industry Opportunities and Challenges
  4. 2.4 Mild Moderate Primary Hypertension Drugs Industry Restraints
3 Mild Moderate Primary Hypertension Drugs Market by Manufacturers
  1. 3.1 Global Mild Moderate Primary Hypertension Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Mild Moderate Primary Hypertension Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Mild Moderate Primary Hypertension Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Mild Moderate Primary Hypertension Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Mild Moderate Primary Hypertension Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Mild Moderate Primary Hypertension Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Mild Moderate Primary Hypertension Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Mild Moderate Primary Hypertension Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Mild Moderate Primary Hypertension Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Mild Moderate Primary Hypertension Drugs Tier 1, Tier 2, and Tier 3
4 Mild Moderate Primary Hypertension Drugs Market by Type
  1. 4.1 Mild Moderate Primary Hypertension Drugs Type Introduction
  2. 4.1.1 Mild Essential Hypertension Drugs
  3. 4.1.2 Moderate Essential Hypertension Drugs
  4. 4.2 Global Mild Moderate Primary Hypertension Drugs Sales by Type
  5. 4.2.1 Global Mild Moderate Primary Hypertension Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Mild Moderate Primary Hypertension Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global Mild Moderate Primary Hypertension Drugs Revenue by Type
  9. 4.3.1 Global Mild Moderate Primary Hypertension Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Mild Moderate Primary Hypertension Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Type (2021-2032)
5 Mild Moderate Primary Hypertension Drugs Market by Application
  1. 5.1 Mild Moderate Primary Hypertension Drugs Application Introduction
  2. 5.1.1 Medical
  3. 5.1.2 Others
  4. 5.2 Global Mild Moderate Primary Hypertension Drugs Sales by Application
  5. 5.2.1 Global Mild Moderate Primary Hypertension Drugs Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Mild Moderate Primary Hypertension Drugs Sales by Application (2021-2032)
  7. 5.2.3 Global Mild Moderate Primary Hypertension Drugs Sales Market Share by Application (2021-2032)
  8. 5.3 Global Mild Moderate Primary Hypertension Drugs Revenue by Application
  9. 5.3.1 Global Mild Moderate Primary Hypertension Drugs Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Mild Moderate Primary Hypertension Drugs Revenue by Application (2021-2032)
  11. 5.3.3 Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Application (2021-2032)
6 Global Mild Moderate Primary Hypertension Drugs Sales by Region
  1. 6.1 Global Mild Moderate Primary Hypertension Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Mild Moderate Primary Hypertension Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Mild Moderate Primary Hypertension Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Mild Moderate Primary Hypertension Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Mild Moderate Primary Hypertension Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Mild Moderate Primary Hypertension Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Mild Moderate Primary Hypertension Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Mild Moderate Primary Hypertension Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Mild Moderate Primary Hypertension Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Mild Moderate Primary Hypertension Drugs Revenue by Region
  1. 7.1 Global Mild Moderate Primary Hypertension Drugs Revenue by Region
  2. 7.1.1 Global Mild Moderate Primary Hypertension Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Mild Moderate Primary Hypertension Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Mild Moderate Primary Hypertension Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Mild Moderate Primary Hypertension Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Mild Moderate Primary Hypertension Drugs Revenue (2021-2032)
  8. 7.2.2 North America Mild Moderate Primary Hypertension Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Mild Moderate Primary Hypertension Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Mild Moderate Primary Hypertension Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Mild Moderate Primary Hypertension Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Mild Moderate Primary Hypertension Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Mild Moderate Primary Hypertension Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Mild Moderate Primary Hypertension Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhejiang Multinpharma Co., Ltd.
  2. 8.1.1 Zhejiang Multinpharma Co., Ltd. Company Information
  3. 8.1.2 Zhejiang Multinpharma Co., Ltd. Business Overview
  4. 8.1.3 Zhejiang Multinpharma Co., Ltd. Mild Moderate Primary Hypertension Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Zhejiang Multinpharma Co., Ltd. Mild Moderate Primary Hypertension Drugs Product Portfolio
  6. 8.1.5 Zhejiang Multinpharma Co., Ltd. Recent Developments
  7. 8.2 SHANDONG QIDU PHARMACEUTICAL CO.,LTD.
  8. 8.2.1 SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Company Information
  9. 8.2.2 SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Business Overview
  10. 8.2.3 SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Mild Moderate Primary Hypertension Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Mild Moderate Primary Hypertension Drugs Product Portfolio
  12. 8.2.5 SHANDONG QIDU PHARMACEUTICAL CO.,LTD. Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Mild Moderate Primary Hypertension Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Mild Moderate Primary Hypertension Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 NanJing EASEHEAL Pharmaceutieal Co.,Ltd.
  20. 8.4.1 NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Company Information
  21. 8.4.2 NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Business Overview
  22. 8.4.3 NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Mild Moderate Primary Hypertension Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Mild Moderate Primary Hypertension Drugs Product Portfolio
  24. 8.4.5 NanJing EASEHEAL Pharmaceutieal Co.,Ltd. Recent Developments
  25. 8.5 Lianhuan Pharma
  26. 8.5.1 Lianhuan Pharma Company Information
  27. 8.5.2 Lianhuan Pharma Business Overview
  28. 8.5.3 Lianhuan Pharma Mild Moderate Primary Hypertension Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Lianhuan Pharma Mild Moderate Primary Hypertension Drugs Product Portfolio
  30. 8.5.5 Lianhuan Pharma Recent Developments
  31. 8.6 China Resources Double-Crane Pharmaceutical Co.,Ltd.
  32. 8.6.1 China Resources Double-Crane Pharmaceutical Co.,Ltd. Company Information
  33. 8.6.2 China Resources Double-Crane Pharmaceutical Co.,Ltd. Business Overview
  34. 8.6.3 China Resources Double-Crane Pharmaceutical Co.,Ltd. Mild Moderate Primary Hypertension Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 China Resources Double-Crane Pharmaceutical Co.,Ltd. Mild Moderate Primary Hypertension Drugs Product Portfolio
  36. 8.6.5 China Resources Double-Crane Pharmaceutical Co.,Ltd. Recent Developments
  37. 8.7 LIFEON GROUP
  38. 8.7.1 LIFEON GROUP Company Information
  39. 8.7.2 LIFEON GROUP Business Overview
  40. 8.7.3 LIFEON GROUP Mild Moderate Primary Hypertension Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 LIFEON GROUP Mild Moderate Primary Hypertension Drugs Product Portfolio
  42. 8.7.5 LIFEON GROUP Recent Developments
  43. 8.8 Beijing UNION Pharmaceutical FACTORY
  44. 8.8.1 Beijing UNION Pharmaceutical FACTORY Company Information
  45. 8.8.2 Beijing UNION Pharmaceutical FACTORY Business Overview
  46. 8.8.3 Beijing UNION Pharmaceutical FACTORY Mild Moderate Primary Hypertension Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Beijing UNION Pharmaceutical FACTORY Mild Moderate Primary Hypertension Drugs Product Portfolio
  48. 8.8.5 Beijing UNION Pharmaceutical FACTORY Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Mild Moderate Primary Hypertension Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Mild Moderate Primary Hypertension Drugs Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Mild Moderate Primary Hypertension Drugs Value Chain Analysis
  2. 9.1.1 Mild Moderate Primary Hypertension Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Mild Moderate Primary Hypertension Drugs Production Mode & Process
  6. 9.2 Mild Moderate Primary Hypertension Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Mild Moderate Primary Hypertension Drugs Distributors
  9. 9.2.3 Mild Moderate Primary Hypertension Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst